APAC In Situ Hybridization Market Size, Share & Trends

Updated on : September 24, 2024

Overview of the APAC In Situ Hybridization Market

APAC In Situ Hybridization market forecasted to transform from $363 million in 2022 to $744 million by 2027, driven by a CAGR of 15.4%. The research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

In developed countries, high-quality molecular diagnostic tests are readily available. However, in developing countries, the cost of these diagnostic technologies is very high, which often makes them unaffordable for a large part of the population. Moreover, the lack of a commercial market for diagnostic procedures has resulted in the availability of a small number of diagnostic tests in developing countries. As a result, emerging markets such as India, China, and South Korea offer significant growth opportunities for MDx-based technologies (including ISH) owing to the rising geriatric population, the growing prevalence of infectious diseases and various types of cancers, the improving healthcare infrastructure, and increasing investments by respective government bodies and leading players in these countries.

Attractive Opportunities in the APAC in Situ Hybridization Market

To know about the assumptions considered for the study, Request for Free Sample Report

APAC In Situ Hybridization Market Dynamics

Driver: Rising incidence of genetic disorders and cancer

Clinical trials pertaining to genetic disorders increased most significantly in the Asia Pacific region. The number of trials conducted increased by 184% between 2010 and 2020. Japan accounted for the largest share, with 28.4% of all trials in the region taking place in Japan in 2020. Australia (25%) and China (21.6%) accounted for the second- and third-largest shares of the overall number of ongoing trials in the region. Moreover, Southeast Asians are more likely to have genetic disorders, according to a study led by co-senior authors Dr. Kumaraswamy Thangaraj of the CSIR-Centre for Cellular and Molecular Biology (CCMB) and Dr. David Reich of the Broad Institute of MIT and Harvard, Cambridge, US, in collaboration with other institutes.

Challenge: Shortage of skilled professionals

In Situ hybridization requires high technical know-how. For instance, understanding of the molecular information of a chromosome or a gene is crucial for conducting ISH tests. Moreover, there is a reluctcance to move from tradional approaches to IT-based approaches such as in situ hybridization. Thus, the shortage of skilled professionals for conducting in situ hybridization tests will hinder the market growth over the forecast period.

The consumables accounted for the largest share of the APAC in situ hybridization industry

The APAC in situ hybridization market is segmented into consumables, instruments, and software based on product. In 2021, the ISH consumables segment accounted for the largest share of this market. The growing government and private funding in life sciences and cancer research, the increasing number of reagent rental agreements, and the application of innovative technologies and methodologies in the fields of tissue and in vitro diagnostics are expected to drive the growth of the consumables market during the forecast period.

The DNA FISH technology segment dominated the fluorescent APAC in situ hybridization industry

Based on the technology, the APAC in situ hybridization market is FISH (fluorescent in situ hybridization) and CISH (chromogenic in situ hybridization). The FISH segment is further categorized into DNA FISH, RNA FISH, and PNA FISH. In 2021, the FISH segment dominated the market with the highest revenue share as FISH is better for data analysis as FISh offers better visuals on software.

In 2021, hospitals & diagnostic laboratories generated the highest revenue in the APAC in situ hybridization industry.

Based on the end user, the APAC in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies. In 2021, the hospital & diagnostic laboratories generated the second highest revenue in the market.The growing patient population, increase in Medicare reimbursements for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests are some of the key factors driving the growth of this end-user segment.

Japan was the largest market for Asia Pacific in situ hybridization industry in 2021.

Companies in Japan are increasingly focusing on revolutionizing the field of precision oncology and personalized medicine with the integration of genetics and proteomics diagnosis. Several collaborations have been observed in the country, which support the research industry in Japan. This trend is expected to continue in the coming years and contribute to market growth in Japan.

To curb the growing incidence of chronic diseases, the Japanese government has been taking initiatives for targeted treatments & personalized therapies, such as the establishment of the Center for Cancer Genomics and Advanced Therapeutics. This initiative is the focal point through which the government aims to aggregate and manage public information on genomic medicine. Efforts like these will also favor market growth in the country.

To know about the assumptions considered for the study, download the pdf brochure

Prominent players in the APAC in situ hybridization market include Abbott Laboratories (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Merck (Germany), F. Hoffmann-La Roche (Switzerland), BioView (Israel), Agilent Technologies (US), Biocare Medical (US), Bio-Techne Corporation (US), QIAGEN (Germany), PerkinElmer (US), Enzo Biochem (US), Bio-Rad Laboratories (US), Abnova Corporation (Taiwan), BioGenex Laboratories (US), OpGen (US), Bio SB (US), Abcam (UK), Zytomed (Germany), 10x Genomics Inc. (US), and NeoGenomics Laboratories (US).

Scope of the APAC In Situ Hybridization Industry

This report categorizes the APAC in situ hybridization market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Consumables
• Kits & Reagents
• Probes
• Accessories
• Instruments
• Software

By Technology

• FISH
• DNA FISH
• RNA FISH
• PNA FISH
• CISH

By Application

• Cancer Diagnostics
• Cytology
• Infectious Disease Diagnostics
• Neuroscience
• Immunology

By End User

• Hospitals and Diagnostic Laboratories
• Academic and Research Institutes
• CROs
• Pharmaceutical and Biotechnology Companies

By Region

• Japan
• China
• India
• South Korea
• Taiwan
• Singapore
• Australia
• New Zealand
• Rest of Asia Pacific (RoAPAC)

Recent Developments of APAC In Situ Hybridization Industry

• In 2022, RNAscope ISH Detection Kit manufactured by Bio-Techne received CE-IVD approval for the BOND-III platform (Leica Biosystems).
• In 2021, Applied Spectral Imaging (ASI) and KromaTiD, Inc. entered a strategic commercial partnership granting ASI worldwide rights to market KromaTiD’s proprietary Pinpoint FISH (PPF) probes and assay services.
• In 2020, Creative Bioarray introduced an advanced FISH probe to detect the 2019 Novel Coronavirus.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst